Health programs crave for diagnostic imaging and eradication of chemoresistant neoplastic lesions smaller than 1 mm of size.
PHIRE aims at bringing closer to market a novel high-resolution theranostic medical device effective in the clinical applications for lesions <1 mm, ready for application in human bladder cancer and effective both in male and female patients.PHIRE aims at bringing closer to market a novel high-resolution theranostic medical device effective in the clinical applications for lesions <1 mm, ready for application in human bladder cancer and effective both in male and female patients.
Locate and eradicate undetectable bladder cancer lesions
Innovative solutions
Photoacoustic Device Add-ons
A module attached to photoacoustic devices improving imaging of hollow organs.
Gold Nanorods
A large-scale synthesis of urine-stable gold nanords for clinical use.
AI-Driven Prediction Maps
Prediction map of gold nanorods to indicate their concentration, improving effectiveness.
Publications
Multimodal Diagnostic Imaging of Metabolic Dysfunction–Associated Steatotic Liver Disease: Noninvasive Analyses by Photoacoustic Ultrasound and Magnetic Resonance Imaging
Published in The American Journal of Pathology, Volume 195, Issue 5, May 2025.
High-grade non-muscle invasive urothelial carcinoma in dogs and humans share specific expression of integrin α5β1
Published in Frontiers in Oncology, 28 May 2025.
Urine-stable aptamer-conjugated gold nanorods for the early detection of high-grade bladder cancer residual disease
Published in Advanced Healthcare Materials, 11 February 2025.
Gold nanorod–assisted theranostic solution for nonvisible residual disease in bladder cancer
Published in PNAS, 5 September 2024.
Sign Up for Our Newsletter
The PHIRE consortium
The PHIRE consortium follows a multicultural and multidisciplinary approach (urology, radiology, biology, nanotechnology, chemistry and mathematical modelling), bringing together scientists with a proven track record of >400 manuscripts.
Start date/End date
01-09-2023
31-08-2026
EU Contribution
Coordinated By
OSPEDALE SAN RAFFAELE SRL
